Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 18, Number 1—January 2012


Modeling Insights into Haemophilus influenzae Type b Disease, Transmission, and Vaccine Programs

Michael L. Jackson1Comments to Author , Charles E. Rose, Amanda Cohn, Fatima Coronado, Thomas A. Clark, Jay D. Wenger, Lisa Bulkow, Michael G. Bruce, Nancy E. Messonnier, and Thomas W. Hennessy
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure 3

Figure 3. Predicted effects of extended Haemophilus influenzae type b (Hib) vaccine shortage on the incidence of invasive Hib disease in the United States (A) and of switching from PRP-OMP to PRP-T vaccine in the Alaska Native population (B). See text for complete description of shortage scenarios. PRP-OMP, Hib polyribosylribitol phosphate polysaccharide conjugated to Neisseria meningitidis outer membrane protein; PRP-T, polyribosylribitol phosphate polysaccharide conjugated to tetanus toxoid.

Main Article

1Current affiliation: Group Health Research Institute, Seattle, Washington, USA.

Top of Page


Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order

CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You… The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO